{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:58:42Z","timestamp":1792180722495,"version":"4.4.0"},"reference-count":17,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>NF-\u03baB, a transcription factor essential for inflammatory responses, is constitutively activated in many lymphomas. In preclinical studies, pelabresib (CPI-0610), an investigational (BET) bromodomain inhibitor, downregulated NF-\u03baB signaling and demonstrated antitumor activity in vitro. Here we report the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity from the first-in-human phase I study of pelabresib in patients with relapsed\/refractory lymphomas (NCT01949883).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Sixty-four patients with relapsed\/refractory lymphoma (median of 4 prior lines of therapy) were treated with either capsule (6, 12, 24, 48, 80, 120, 170, 230, 300 mg) or tablet (125, 225 mg) doses of pelabresib orally once daily on a 14\u2009days on, 7 days off schedule.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The MTD was determined as the 225 mg tablet daily. The most frequent adverse events were fatigue, nausea, and decreased appetite. Thrombocytopenia, a class effect for all BET inhibitors, was dose-dependent, reversible, and noncumulative. Pelabresib exhibited dose-proportional increases in systemic exposure, rapid absorption, and a half-life of approximately 15\u2009hours (supporting once daily dosing). The bioavailability of the tablet formulation was 60% greater than the capsules. Pelabresib suppressed IL8 and CCR1 mRNA at doses above 120 and 170 mg, respectively. Four patients (6.2%) had an objective response (2 complete response and 2 partial response) and 5 patients had prolonged stable disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/Discussion:<\/jats:title>\n                    <jats:p>Pelabresib is capable of BET target gene suppression in an exposure-dependent manner with an acceptable safety profile leading to the recommended phase II dose of the 125 mg tablet once daily.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>BET proteins inhibition can potentially modify the pathogenic pathways which contribute to many diseases including malignancies. Pelabresib (CPI-0610), a potent and selective small molecule BET proteins inhibitor, has a MTD of 225 mg once daily for 14 days with a 7-day break, clear pharmacokinetic\/pharmacodynamic relationship, and manageable clinical safety profile. These findings are part of the foundation for the ongoing pivotal study of pelabresib in patients with myelofibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0060","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T09:34:52Z","timestamp":1657877692000},"page":"795-805","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-9794","authenticated-orcid":true,"given":"Kristie A.","family":"Blum","sequence":"first","affiliation":[{"name":"1Emory University School of Medicine, Atlanta, Georgia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4599-3267","authenticated-orcid":true,"given":"Jeffrey G.","family":"Supko","sequence":"additional","affiliation":[{"name":"2Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Maris","sequence":"additional","affiliation":[{"name":"3Colorado Blood Cancer Institute, Denver, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-290X","authenticated-orcid":true,"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[{"name":"4Sarah Cannon Research Institute and Tennessee Oncology PLLC, Nashville, Tennessee."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5125-6522","authenticated-orcid":true,"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"5John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"6Memorial Sloan Kettering Cancer Center, New York City, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8003-0634","authenticated-orcid":true,"given":"Suresh","family":"Bobba","sequence":"additional","affiliation":[{"name":"7Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Senderowicz","sequence":"additional","affiliation":[{"name":"7Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Efuni","sequence":"additional","affiliation":[{"name":"7Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronda","family":"Rippley","sequence":"additional","affiliation":[{"name":"7Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Colak","sequence":"additional","affiliation":[{"name":"8Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-9154","authenticated-orcid":true,"given":"Patrick","family":"Trojer","sequence":"additional","affiliation":[{"name":"7Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":true,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"2Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The mechanisms behind the therapeutic activity of BET bromodomain inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol Cell"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"11365","DOI":"10.1073\/pnas.1411701111","article-title":"Blockade of oncogenic I\u03baB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors","volume":"111","author":"Ceribelli","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-LB-038","article-title":"Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients","author":"Tsujikawa","year":"2017"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET Proteins as Targets for Anticancer Treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1182\/blood.V126.23.1491.1491","article-title":"BET Inhibitor CPl-0610 Is well tolerated and induces responses in diffuse large B-cell lymphoma and follicular lymphoma: preliminary analysis of an ongoing phase 1 study","volume":"126","author":"Abramson","year":"2015","journal-title":"Blood"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1021\/acs.jmedchem.5b01882","article-title":"Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials","volume":"59","author":"Albrecht","year":"2016","journal-title":"J Med Chem"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023031315395902500_","first-page":"504","article-title":"Bromodomain inhibitors: what does the future hold?","volume":"16","author":"Bhattacharya","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"2023031315395902500_","article-title":"The BET inhibitor CPI-0610 promotes myeloid differentiation in myelofibrosis patient bone marrow and peripheral CD34+ hematopoietic stem cells","author":"Mertz","year":"2020","journal-title":"American Society of Hematology"},{"key":"2023031315395902500_","article-title":"BET inhibitor pelabresib decreases inflammatory cytokines, improves bone marrow fibrosis and function, and demonstrates clinical response irrespective of mutation status in myelofibrosis patients","author":"Keller","year":"2021","journal-title":"European Hematology Association"},{"key":"2023031315395902500_","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0060\/3180469\/crc-22-0060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/795\/3282569\/crc-22-0060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/795\/3282569\/crc-22-0060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T11:27:37Z","timestamp":1700825257000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/8\/795\/707624\/A-Phase-I-Study-of-Pelabresib-CPI-0610-a-Small"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,11]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0060","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545002.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545008.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550823","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544999","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545005.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545002","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550823.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22544999.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545005","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}